record state
frontier-ownedReview status
This finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
accepted
frontiers / frontier
Finding bundle
back to stateno incoming links yet
record state
frontier-ownedThis finding is part of accepted frontier state. Review events, reviewable changes, and proof state explain how it can change.
finding statement
finding typeNo entity list is declared.
evidence
source-boundobservational · manual state transition · Homo sapiens
proof impact
packet context2 reviewable changes and 0 evaluation records are attached to this finding id.
Evidence and conditions
method
manual state transition
evidence type
observational
species
Homo sapiens
evidence spans
Field consensus 2018-2022 shifted from soluble-Aβ targeting (solanezumab class) to aggregated-Aβ + protofibril targeting (lecanemab, donanemab, aducanumab); EXPEDITION3 read as definitive evidence that soluble Aβ is downstream marker not therapeutic substrate.
Cascade-densification deposit: Solanezumab EXPEDITION3 failure (Honig 2018) → broader anti-Aβ MAb scope refinement · curator_source · Cascade-densification deposit: Solanezumab EXPEDITION3 failure (Honig 2018) → broader anti-Aβ MAb scope refinement
conditions
Provenance
source title
Cascade-densification deposit: Solanezumab EXPEDITION3 failure (Honig 2018) → broader anti-Aβ MAb scope refinement
authors
reviewer:will-blair-bot
Field consensus 2018-2022 shifted from soluble-Aβ targeting (solanezumab class) to aggregated-Aβ + protofibril targeting (lecanemab, donanemab, aducanumab); EXPEDITION3 read as definitive evidence that soluble Aβ is downstream marker not therapeutic substrate.
vs_c06a1be73809d6e0 · source:Cascade-densification deposit: Solanezumab EXPEDITION3 failure (Honig 2018) → broader anti-Aβ MAb scope refinement|section:curator_source · manual_curation
outgoing
No outgoing links.
incoming
No incoming links.
events
vev_0bb55211bc66258dfinding.assertedManual finding added to frontier state
reviewer:will-blair-bot · 2026-05-06
vev_66d0f35c86c36f5cfinding.reviewedAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
reviewer:will-blair-bot · 2026-05-06
reviewable changes
vpr_1cdb7be6b81b9c26finding.reviewAccepted as a broad-frontier seed inside the anti-amyloid scope; source locator remains the authority.
applied · reviewer:will-blair-bot · 2026-05-06
vpr_243c0195a9f529aefinding.addManual finding added to frontier state
applied · reviewer:will-blair-bot · 2026-05-06
evaluations
No evaluation record targets this finding id.